• Explore /
  • Poster
  • / Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.

Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.

Abstract Poster

Authors

null

Elena Schönlau

Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC, Canada

Elena Schönlau , David Christian Müller , Gillian Vandekerkhove , Andrew Murtha , Jack V.W. Bacon , Connor Wells , Kimia Rostin , Sunil Parimi , Krista Noonan , Naveen S. Basappa , Jenny J. Ko , Daygen L. Finch , Nimira S. Alimohamed , Tarek A. Bismar , Lucia Nappi , Matti Annala , Cecily Q. Bernales , Kim N. Chi , Alexander William Wyatt , Bernhard J. Eigl

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4577)

DOI

10.1200/JCO.2023.41.16_suppl.4577

Abstract #

4577

Poster Bd #

69

Abstract Disclosures

Similar Posters

First Author: Benjamin Garmezy

First Author: James J. Harding

First Author: Lipika Goyal

First Author: Arlene O. Siefker-Radtke